- Companies
- Prenuvo
Prenuvo Funding, Investors & Competitors
Prenuvo has raised $190M across 2 funding rounds, most recently a $120M Series B in February 2025.
Last Prenuvo funding round
$120M
Series B · Feb 2025
Cumulative funding Prenuvo raised
$190M
across 2 funding rounds
Key investors in Prenuvo
Felicis
Forerunner
Left Lane Capital
Anne Wojcicki
Tony Fadell
Timothy A. Springer
Steel Perlot
Cindy Crawford
About Prenuvo
Prenuvo is a San Francisco-headquartered provider of non-contrast whole-body MRI scans for early disease detection. Its 60-minute scans screen for over 500 conditions including cancers using AI-enhanced imaging. Available in clinics across the U.S. and Canada, Prenuvo serves proactive health consumers with radiation-free diagnostics. The company expanded to New York and Dallas locations since launching in 2019.
Founded
2018
HQ
Website
Status
Privately held
Customer focus
B2C
Revenue model
Services
Prenuvo Funding History
Prenuvo has raised a total of $190M across 2 funding rounds.
Prenuvo's first fundraising round was a $70M Series A in October 2022. The most recent completed round was a $120M Series B in February 2025.
Prenuvo funding rounds
| Date | Stage | Investors | Raised | Deal Summary |
|---|---|---|---|---|
| Feb 2025 | Series B | Felicis (lead); Forerunner (lead); Left Lane Capital (lead) | $120M | Prenuvo is a health technology company offering proactive whole-body MRI screening for early detection of cancer and other diseases, using radiation-free, non-invasive scans completed in under 60 minutes. The company, founded in 2018 and headquartered in Redwood City, California, announced on February 13, 2025, that it had raised $120 million as part of its Series B fundraising conducted during 2024. This round was co-led by Forerunner Ventures, Left Lane Capital, and existing investor Felicis, accelerating expansion of core MRI screening with additional modalities and analyses. Alongside the funding disclosure, Prenuvo secured FDA clearance for its AI-powered Prenuvo Body Composition report, assessing visceral fat, subcutaneous fat, liver fat, muscle volume, and abdominal organ volume. The company also launched other advances including a brain health scan evaluating blood flow and a blood biomarker assessment for metabolic, cardiovascular, hormonal, and immune factors. These enhancements build on Prenuvo surpassing 110,000 members and identifying over 1.4 million personalized health insights. Prenuvo operates 17 clinics with 15 more planned, offering scans priced from $1,000 for torso to $2,500 for whole-body, and a new $3,999-$4,499 Enhanced Screening bundle initially in Silicon Valley, Los Angeles, and New York City. The company has raised a total of approximately $190-191.8 million across rounds, including a prior $85 million filing noted around February 14, 2025, and positions itself amid growing investor interest in body scan startups despite medical debates on efficacy and risks of unnecessary follow-ups. Quotes from investors highlight consumer shifts toward preventative health, with Left Lane Capital's Harley Miller noting patients demanding proactive solutions outside traditional systems, and Felicis' Sundeep Peechu praising Prenuvo's unique integrated model for leading healthcare transformation. |
| Oct 2022 | Series A | Felicis (lead); Tony Fadell; Rande Gerber; Timothy A. Springer; Anne Wojcicki; Cindy Crawford; Steel Perlot | $70M | Prenuvo is a pioneer in advanced, radiation-free whole-body MRI imaging for early detection of cancer and other diseases, offering proactive preventive healthcare scans. The company raised $70M in a Series A round on October 18, 2022, comprising equity and debt, led by Felicis with participation from Anne Wojcicki (23andMe CEO), Cindy Crawford, Rande Gerber, Steel Perlot, Timothy A. Springer, and Tony Fadell. Funds are allocated to expand the AI team, develop new radiology tools, build custom advanced MRI systems, and support national clinic expansion including new locations in New York City, Chicago, Boston, and Bethesda. At the time, Prenuvo operated seven clinics across the US and Canada, including recent openings in Santa Monica and Boca Raton, with headquarters in Redwood City, California. The company reported 240% year-over-year revenue growth and was scaling rapidly. Each scan was priced at about $1,000, with plans to reduce costs to $200-$300 for better accessibility. The mission emphasizes shifting healthcare from reactive to proactive by detecting conditions early. |
Who has invested in Prenuvo?
9 investors have backed Prenuvo across its funding rounds, including Felicis, Forerunner, Left Lane Capital, Anne Wojcicki, Tony Fadell and Timothy A. Springer.
Lead investors include Felicis, Forerunner and Left Lane Capital.
Prenuvo Investors
| Investor | HQ | Rounds | Role | First check |
|---|---|---|---|---|
| 2 | Lead | Oct 2022 | ||
| 1 | Lead | Feb 2025 | ||
| 1 | Participant | Oct 2022 | ||
| 1 | Lead | Feb 2025 | ||
| 1 | Participant | Oct 2022 | ||
| 1 | Participant | Oct 2022 | ||
| 1 | Participant | Oct 2022 | ||
This data is available for Pro users. Sign up to see all 9 Prenuvo investors. Start Free Trial | ||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialPrenuvo Competitors
Prenuvo competitors include listed companies like Detection Technology, GE HealthCare, United Imaging and Lantheus Holdings, and private ones like United Imaging Intelligence and Carestream.
| Company | HQ | Status | Revenue | EBITDA | Valuation | Revenue Multiple |
|---|---|---|---|---|---|---|
| Publicly listed | $116M | $11M | $128M | 0.9x | ||
| Publicly listed | $21B | $3.7B | $29B | 1.8x | ||
| Publicly listed | $2.1B | $367M | $12B | 4.8x | ||
| Publicly listed | $1.5B | $380M | $6.6B | 4.4x | ||
| Private | - | - | $1.4B | - | ||
| Private | - | - | $800M | - |
Prenuvo Public Comps
Prenuvo is still privately-owned, but its public comps include Natera, Agilent, GE HealthCare, Quest Diagnostics, Labcorp, Guardant Health, Revvity, Pro Medicus, United Imaging and bioMérieux.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $2.3B | ($266M) | 22.5x | 19.0x | (195.0x) | (261.5x) | |||
| $6.9B | $1.8B | 6.7x | 6.2x | 26.1x | 21.0x | |||
| $21B | $3.7B | 1.8x | 1.8x | 10.1x | 10.0x | |||
| $11B | $2.2B | 3.0x | 2.9x | 15.5x | 14.5x | |||
| $14B | $2B | 2.4x | 2.3x | 16.3x | 13.0x | |||
| $982M | ($408M) | 25.7x | 20.2x | (61.8x) | (129.5x) | |||
| $2.9B | $735M | 6.5x | 6.6x | 25.4x | 21.0x | |||
| $186M | $147M | 66.6x | 62.7x | 84.4x | 77.6x | |||
This data is available for Pro users. Sign up to see all Prenuvo competitors and their valuation data. Start Free Trial | ||||||||
Common questions about Prenuvo
| When was Prenuvo founded? | Prenuvo was founded in 2018. |
| Where is Prenuvo headquartered? | Prenuvo is headquartered in Vancouver, Canada. |
| Is Prenuvo publicly listed? | No, Prenuvo is a private, VC-backed company. |
| How much funding has Prenuvo raised? | Prenuvo has raised $190M across 2 funding rounds. |
| What was Prenuvo's last funding round? | Prenuvo's last funding round was a $120M Series B in February 2025, led by Felicis, Forerunner and Left Lane Capital. |
| Who are Prenuvo's investors? | Prenuvo's investors include Felicis, Left Lane Capital, Tony Fadell, Forerunner, Rande Gerber, Timothy A. Springer, Anne Wojcicki, Cindy Crawford and Steel Perlot. |
| Which companies are comparable to Prenuvo? | Companies comparable to Prenuvo include Detection Technology, GE HealthCare, United Imaging, Lantheus Holdings, United Imaging Intelligence and Carestream. |
See companies similar to Prenuvo
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




